

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Viventia Biotechnologies Inc.	08/09/2013
RECEIVING PARTY DATA	
Name:	VIVENTIA BIO INC.
Street Address:	147 Hamelin Street
City:	Winnipeg, MB
State/Country:	CANADA
Postal Code:	R3T 3Z1
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	5639863
CORRESPONDENCE DATA	
Fax Number:	4122810717
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	412-454-5000
Email:	docketingpgh@pepperlaw.com
Correspondent Name:	Pepper Hamilton LLP
Address Line 1:	500 Grant Street
Address Line 2:	Suite 5000
Address Line 4:	Pittsburgh, PENNSYLVANIA 15219-2507
ATTORNEY DOCKET NUMBER:	140260.01701
NAME OF SUBMITTER:	N. Nicole Endejann, Reg. No. 50229
Signature:	/N. Nicole Endejann/
Date:	09/05/2013
Total Attachments: 9	

OP \$40.00 5639863

source=Executed_Short_Form_Assignment_ViventaBiotechnologies_to_ViventiaBioInc#page1.tif
source=Executed_Short_Form_Assignment_ViventaBiotechnologies_to_ViventiaBioInc#page2.tif
source=Executed_Short_Form_Assignment_ViventaBiotechnologies_to_ViventiaBioInc#page3.tif
source=Executed_Short_Form_Assignment_ViventaBiotechnologies_to_ViventiaBioInc#page4.tif
source=Executed_Short_Form_Assignment_ViventaBiotechnologies_to_ViventiaBioInc#page5.tif
source=Executed_Short_Form_Assignment_ViventaBiotechnologies_to_ViventiaBioInc#page6.tif
source=Executed_Short_Form_Assignment_ViventaBiotechnologies_to_ViventiaBioInc#page7.tif
source=Executed_Short_Form_Assignment_ViventaBiotechnologies_to_ViventiaBioInc#page8.tif
source=Executed_Short_Form_Assignment_ViventaBiotechnologies_to_ViventiaBioInc#page9.tif

ASSIGNMENT

THIS ASSIGNMENT is made effective as of 2nd day of January 2013.

WHEREAS, **VIVENTIA BIOTECHNOLOGIES INC.**, a corporation existing under the laws of the Province of Ontario, having a business address at 147 Hamelin Street, Winnipeg, MB R3T 3Z1, (hereinafter referred to as "ASSIGNOR"), is the ASSIGNEE of certain inventions as set forth in Exhibit A (hereinafter collectively referred to as "PATENT PROPERTY").

WHEREAS, **VIVENTIA BIO INC.**, a corporation existing under the laws of the Province of Ontario, having a business address at 147 Hamelin Street, Winnipeg, MB R3T 3Z1, (hereinafter referred to as "ASSIGNEE"), is desirous of acquiring the entire right, title and interest in and to said INVENTIONS and in and to any and all Letters Patent of the United States and foreign countries that may be obtained therefor for said INVENTIONS.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR, intending to be legally bound, has sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over to said ASSIGNEE, the entire right, title and interest in and to said PATENT PROPERTY and any and all continuations, divisions and renewals of and substitutes for said PATENT PROPERTY and to and under any and all additional Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and the full right to sue for and recover all profits and damages recoverable for past infringement of the same, and assign to and authorize said ASSIGNEE to file applications for Letters Patent in all countries, to be held and enjoyed by said ASSIGNEE, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, sale and transfer not been made.

AND it is hereby covenanted that ASSIGNOR has full right to convey my entire interest herein assigned, and that ASSIGNOR has not executed and will not execute any agreement in conflict herewith, and ASSIGNOR further covenants and agrees that it will each time a request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said PATENT PROPERTY in said ASSIGNEE, its successors, assigns, nominees, or legal representatives, and ASSIGNOR agrees to communicate to said ASSIGNEE or to its nominee all known facts respecting said PATENT PROPERTY, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said ASSIGNEE, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said PATENT PROPERTY in any and all countries, all at the expense, however, of said ASSIGNEE, its successors, assigns, nominees, or legal representatives.

THE ASSIGNOR FURTHER WARRANTS AND COVENANTS that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been or will be made to others by the undersigned, and that the full right to convey the same as herein expressed is possessed by the undersigned.

AND ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said ASSIGNEE, as assignee of the entire right, title and interest, any and all Letters Patent for said PATENT PROPERTY, including any and all Letters Patent of the United States which may be issued and granted on or as a result of any applications in said PATENT PROPERTY, in accordance with the terms of this ASSIGNMENT.

IN WITNESS WHEREOF, the undersigned, being properly authorized to execute this ASSIGNMENT, hereunto sets their hand and seal on the 9 day of 2013 2013.

VIVENTIA BIOTECHNOLOGIES INC.

By: Leslie Dan
Name: Leslie Dan
Chairman

VIVENTIA BIO INC.

By: Leslie Dan
Name: Leslie Dan
Chairman

STATEMENT OF WITNESS

SIGNED at TORONTO ONTARIO CANADA
(City) (Country)

This 9 day of AUGUST, 2013.

I, LOERNAINE SATINARINE, whose full residence address is
1655 PICKERING PARKWAY, PICKERING ON L1V6L3

was personally present and did witness **Leslie Dan** execute the above ASSIGNMENT on the 9 day of AUGUST, 2013, and is personally known to me to be the person described in such document.

Loeraine Satinarine
Signature of Witness

EXHIBIT A

Case Number	Sub Case	Country	Application Number	File Date	Patent Number	Issue Date	Application Title
140260.001	02	WO	US1997/008962	05/22/1997			ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS
140260.001	03	EP	97929703.3	05/22/1997	0912738	07/30/2008	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS
140260.001	04	JP	9-542853	05/22/1997	4124486	05/16/2008	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS
140260.001	05	CA	2255540	05/22/1997	2255540	05/15/2007	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS
140260.001	07	AU	19970033693	05/22/1997	725238	10/12/2000	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDE ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION
140260.001	08	IL	127193	05/22/1997	127193	02/01/2007	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS
140260.001	09	FR	97929703.3	05/22/1997	0912738	07/30/2008	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS
140260.001	11	US	08/862124	05/22/1997	6207153	03/27/2001	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS
140260.001	17	AU	72432400	05/22/1997	775448	02/24/2005	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS
140260.001	18	DE	69738868.9	05/22/1997	0912738	07/30/2008	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS

PATENT

REEL: 031144 FRAME: 0370

Case Number	Sub Case	Country	Application Number	File Date	Patent Number	Issue Date	Application Title
140260.001	19	GB	97929703.3	05/22/1997	0912738	07/30/2008	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS
140260.001	31	US	10/651453	08/29/2003	7166286	01/23/2007	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS
140260.001	41	US	09/194164	04/09/1999	7115722	10/03/2006	ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS
140260.004	01	US	11/722420	06/21/2007	8084576	12/27/2011	CANCER ASSOCIATED GLUCOSE TRANSPORTER 8 VARIANT
140260.004	02	WO	CA2005/001953	12/21/2005			CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS
140260.004	03	EP	05823959.1	12/21/2005	1833968	04/17/2013	CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS
140260.004	04	JP	2007-547125	12/21/2005	5143566	11/30/2012	CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS
140260.004	05	CA	2591768	12/21/2005			CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS
140260.004	07	AU	2005318836	12/21/2005	2005318836	07/05/2012	CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS
140260.004	08	CN	200580048522.8	12/21/2005	200580048522.8	06/05/2013	CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS
140260.004	09	IL	183958	12/21/2005	183958	05/30/2012	CANCER ASSOCIATED VARIANT OF GLUCOSE TRANSPORTER 8 AND USE THEREOF IN TREATING AND DETECTING CANCER
140260.004	11	US	13/297783	11/16/2011			CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS
140260.004	14	JP	2012-207216	09/20/2012			CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS
140260.004	18	HK	08109579.2	08/28/2008			CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS
140260.004	19	IN	5064/DELNP/2007	12/21/2005			CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS
140260.004	28	NZ	556055	12/21/2005	556055	04/08/2010	CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS
140260.004	29	ZA	2007/05837	12/21/2005	2007/05837	05/28/2008	CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS

PATENT

REEL: 031144 FRAME: 0371

Case Number	Sub Case	Country	Application Number	File Date	Patent Number	Issue Date	Application Title
140260.004	38	DE	05823959.1	12/21/2005	1833968	04/17/2013	PROTEINS CANCER SPECIFIC ANTIBODY AND CELL SURFACE
140260.004	39	FR	05823959.1	12/21/2005	1833968	04/17/2013	PROTEINS CANCER SPECIFIC ANTIBODY AND CELL SURFACE
140260.004	48	IT	05823959.1	12/21/2005	1833968	04/17/2013	PROTEINS CANCER SPECIFIC ANTIBODY AND CELL SURFACE
140260.004	49	ES	05823959.1	12/21/2005	1833968	04/17/2013	PROTEINS CANCER SPECIFIC ANTIBODY AND CELL SURFACE
140260.004	58	GB	05823959.1	12/21/2005	1833968	04/17/2013	PROTEINS CANCER SPECIFIC ANTIBODY AND CELL SURFACE
140260.004	59	BE	05823959.1	12/21/2005	1833968	04/17/2013	PROTEINS CANCER SPECIFIC ANTIBODY AND CELL SURFACE
140260.004	68	CH	05823959.1	12/21/2005	1833968	04/17/2013	PROTEINS CANCER SPECIFIC ANTIBODY AND CELL SURFACE
140260.004	69	AT	05823959.1	12/21/2005	1833968	04/17/2013	PROTEINS CANCER SPECIFIC ANTIBODY AND CELL SURFACE
140260.006	01	US	11/570198	06/27/2007	8383117	02/26/2013	CD4E TUMOR SPECIFIC ANTIBODY
140260.006	02	WO	CA2005/000899	06/10/2005			TUMOR SPECIFIC ANTIBODY
140260.006	03	EP	05754865.3	06/10/2005			TUMOR SPECIFIC ANTIBODY
140260.006	04	JP	2007-526144	06/10/2005	5026268	06/29/2012	TUMOR SPECIFIC ANTIBODY
140260.006	05	CA	2569788	06/10/2005			TUMOR SPECIFIC ANTIBODY
140260.006	07	AU	2005252275	06/10/2005	2005252275	11/03/2011	TUMOR SPECIFIC ANTIBODY
140260.006	08	CN	200580027200.5	06/10/2005			TUMOR SPECIFIC ANTIBODY
140260.006	09	HK	08101438.0	02/06/2008			TUMOR SPECIFIC ANTIBODY
140260.006	11	US	13/743672	01/17/2013			TUMOR SPECIFIC ANTIBODY
140260.006	14	JP	2012-078467	03/30/2012			TUMOR SPECIFIC ANTIBODY
140260.006	18	IL	179891	06/10/2005			TUMOR SPECIFIC ANTIBODY
140260.006	19	IN	221/DELNP/2007	06/10/2005			TUMOR SPECIFIC ANTIBODY
140260.006	28	NZ	552476	06/10/2005	552476	01/07/2010	TUMOR SPECIFIC ANTIBODY
140260.006	29	ZA	2007/00145	06/10/2005			TUMOR SPECIFIC ANTIBODY
140260.007	00	US	60/751,965	12/21/2005			NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	01	US	12/097336	11/12/2008	7956162	06/07/2011	CANCER-ASSOCIATED ANTIGEN
140260.007	02	WO	CA2006/002101	12/21/2006			NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	03	EP	06840528.1	12/21/2006	1976987	06/27/2012	NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	04	JP	2008-546058	12/21/2006			NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	05	CA	2633131	12/21/2006			NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	07	AU	2006329198	12/21/2006	2006329198	05/17/2012	NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	08	CN	200680053091.9	12/21/2006			NOVEL CANCER-ASSOCIATED ANTIGEN

PATENT

REEL: 031144 FRAME: 0372

Case Number	Sub Case	Country	Application Number	File Date	Patent Number	Issue Date	Application Title
140260.007	09	IL	192119	12/21/2006			NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	11	US	13/094118	04/26/2011	8389286	03/05/2013	CANCER-ASSOCIATED ANTIGEN
140260.007	14	JP	2013-146257	12/21/2006			NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	18	IN	5549/DELNP/2008	12/21/2006			NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	19	NZ	569450	12/21/2006	569450	05/07/2012	NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	21	US	13/750849	01/25/2013			NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	28	RU	2008129770	12/21/2006	2433136		NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	29	FR	06840528.1	12/21/2006	1976987	06/27/2012	NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	38	DE	06840528.1	12/21/2006	1976987	06/27/2012	NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	39	IT	06840528.1	12/21/2006	1976987	06/27/2012	NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	48	ES	06840528.1	12/21/2006	1976987	06/27/2012	NOVEL CANCER-ASSOCIATED ANTIGEN
140260.007	49	GB	06840528.1	12/21/2006	1976987	06/27/2012	NOVEL CANCER-ASSOCIATED ANTIGEN
140260.008	00	US	60/752,871	12/23/2005			METHODS FOR GENERATING IMMUNOTOXIN LIBRARIES AND USES THEREOF
140260.008	01	US	12/097419	11/10/2008			METHODS FOR GENERATING AND SCREENING FUSION PROTEIN LIBRARIES AND USES THEREOF
140260.008	02	WO	CA2006/002113	12/22/2006			METHODS FOR GENERATING AND SCREENING FUSION PROTEIN LIBRARIES AND USES THEREOF
140260.008	03	EP	06840540.6	12/22/2006			METHODS FOR GENERATING AND SCREENING FUSION PROTEIN LIBRARIES AND USES THEREOF
140260.008	04	JP	2008-546061	12/22/2006			METHODS FOR GENERATING AND SCREENING FUSION PROTEIN LIBRARIES AND USES THEREOF
140260.008	05	CA	2633138	12/22/2006			METHODS FOR GENERATING AND SCREENING FUSION PROTEIN LIBRARIES AND USES THEREOF
140260.008	07	AU	2006329208	12/22/2006	2006329208	06/21/2012	METHODS FOR GENERATING AND SCREENING FUSION PROTEIN LIBRARIES AND USES THEREOF
140260.008	08	CN	200680053419.7	12/22/2006			METHODS FOR GENERATING AND SCREENING FUSION PROTEIN LIBRARIES AND USES THEREOF
140260.008	09	IL	192222	12/22/2006			METHODS FOR GENERATING AND SCREENING FUSION PROTEIN LIBRARIES AND USES THEREOF
140260.008	18	IN	6153/DELNP/2008	12/22/2006			METHODS FOR GENERATING AND SCREENING FUSION PROTEIN LIBRARIES AND USES THEREOF
140260.010	00	US	60/912,732	04/19/2007			NUCLEOTIDE SEQUENCE OPTIMIZED FOR EXPRESSION OF RECOMBINANT PROTEIN
140260.010	01	US	12/596188	02/08/2010	8263744	09/11/2012	BINDING PROTEINS THAT BIND TO EPCAM LINKED TO AN EFFECTOR MOLECULE
140260.010	02	WO	CA2008/000711	04/18/2008			OPTIMIZED NUCLEOTIDE SEQUENCES OF VB6-845 FOR EXPRESSION OF RECOMBINANT PROTEINS
140260.010	05	CA	2684330	04/18/2008			OPTIMIZED NUCLEOTIDE SEQUENCES OF VB6-845 FOR EXPRESSION OF RECOMBINANT PROTEINS

PATENT

REEL: 031144 FRAME: 0373

Case Number	Sub Case	Country	Application Number	File Date	Patent Number	Issue Date	Application Title
140260.011	00	US	60/975,718	09/27/2007			NOVEL NUCLEIC ACID SEQUENCES FOR THE EXPRESSION OF RECOMBINANT PROTEINS
140260.011	01	US	12/679963	06/24/2010	8318472	11/27/2012	OPTIMIZED NUCLEIC ACID SEQUENCES FOR THE EXPRESSION OF VB4-845
140260.011	02	WO	CA2008/001680	09/26/2008			OPTIMIZED NUCLEIC ACID SEQUENCES FOR THE EXPRESSION OF VB4-845
140260.011	05	CA	2700815	09/26/2008			OPTIMIZED NUCLEIC ACID SEQUENCES FOR THE EXPRESSION OF VB4-845
140260.012	00	US	60/982,575	10/25/2007			NOVEL CANCER-ASSOCIATED ANTIBODY AND ANTIGEN
140260.012	01	US	12/738883	07/14/2010	8273550	09/25/2012	ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT HNRNPG AND USES THEREOF
140260.012	02	WO	CA2008/001878	10/23/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT HNRNPG AND USES THEREOF
140260.012	03	EP	08841782.9	10/23/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT HNRNPG AND USES THEREOF
140260.012	04	JP	2010-530235	10/23/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT HNRNPG AND USES THEREOF
140260.012	05	CA	2703140	10/23/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT HNRNPG AND USES THEREOF
140260.012	07	AU	2008316224	10/23/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT HNRNPG AND USES THEREOF
140260.012	08	CN	200880122991.3	10/23/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT HNRNPG AND USES THEREOF
140260.012	09	HK	11107962.6	10/23/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT HNRNPG AND USES THEREOF
140260.012	11	US	13/591715	08/22/2012			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT HNRNPG AND USES THEREOF
140260.013	00	US	60/990,494	11/27/2007			NOVEL CANCER ASSOCIATED ANTIBODY AND ANTIGEN
140260.013	01	US	12/744523	08/31/2010	8426561	04/23/2013	ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT NFKBIB AND USES THEREOF
140260.013	02	WO	CA2008/002076	11/27/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT NFKBIB AND USES THEREOF
140260.013	03	EP	08855248.4	11/27/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT NFKBIB AND USES THEREOF
140260.013	04	JP	2010-535185	11/27/2008			ANTIBODIES AGAINST CANCER-ASSOCIATED EPITOPE OF VARIANT NFKBIB AND USES THEREOF
140260.013	05	CA	2706633	11/27/2008			NOVEL CANCER-ASSOCIATED ANTIBODY AND ANTIGEN

PATENT

REEL: 031144 FRAME: 0374

Case Number	Sub Case	Country	Application Number	File Date	Patent Number	Issue Date	Application Title
140260.013	07	AU	2008329518	11/27/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPI TOPE OF VARIANT NFKBIB AND USES THEREOF
140260.013	08	CN	200880125628.7	11/27/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPI TOPE OF VARIANT NFKBIB AND USES THEREOF
140260.013	09	IL	205773	11/27/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPI TOPE OF VARIANT NFKBIB AND USES THEREOF
140260.013	11	US	13/850899	03/26/2013			ANTIBODY CONJUGATES AGAINST VARIANT NFKBIB AND USES THEREOF
140260.013	18	IL	221841	08/27/2008			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPI TOPE OF VARIANT NFKBIB AND USES THEREOF
140260.013	19	HK	11106080.5	06/14/2011			ANTIBODIES AGAINST A CANCER-ASSOCIATED EPI TOPE OF VARIANT NFKBIB AND USES THEREOF
140260.014	00	US	61/138,979	12/18/2007			BCAM SPECIFIC ANTIBODIES
140260.014	10	US	61/138,979	12/19/2008			BCAM SPECIFIC ANTIBODIES
140260.014	20	US	61/288,374	12/21/2009			BCAM SPECIFIC ANTIBODIES
140260.014	30	US	61/428,803	12/22/2010			BCAM SPECIFIC ANTIBODIES
140260.014	40	US	61/579747	12/23/2011			B-CAM SPECIFIC ANTIBODIES
140260.014	40	US	61/579,747	12/23/2011			BCAM SPECIFIC ANTIBODIES
140260.015	00	US	61/022,997	01/23/2008			VANGL1 SPECIFIC ANTIBODIES
140260.015	10	US	61/147,311	01/26/2009			VANGL1 SPECIFIC ANTIBODIES
140260.015	20	US	61/298,587	01/27/2010			VANGL1 SPECIFIC ANTIBODIES
140260.015	30	US	61/437,026	01/28/2011			VANGL1 SPECIFIC ANTIBODIES
140260.015	40	US	61/592,701	01/31/2012			VANGL1 SPECIFIC ANTIBODIES
140260.015	50	US	61/759739	02/01/2013			ANTIBODIES SPECIFIC FOR VANGL1
140260.016	00	US	61/023,032	01/23/2008			MATRIPTASE SPECIFIC ANTIBODY
140260.016	10	US	61/147,318	01/26/2009			MATRIPTASE SPECIFIC ANTIBODY
140260.016	20	US	61/298,592	01/27/2010			MATRIPTASE SPECIFIC ANTIBODY
140260.016	30	US	61/437,028	01/28/2011			MATRIPTASE SPECIFIC ANTIBODY
140260.016	40	US	61/592,707	01/31/2012			MATRIPTASE SPECIFIC ANTIBODY
140260.016	50	US	61/759804	02/01/2013			ANTIBODIES SPECIFIC FOR A SERINE PROTEASE
140260.017	01	US	08/264093	06/21/1994	5639863	06/17/1997	HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CELL CYCLE INDEPENDENT GLIOMA SURFACE ANTIGEN
140260.018	02	WO	CA2008/000710	04/18/2008			ENDOTOXIN REMOVAL
140260.018	05	CA	2684328	04/18/2008			ENDOTOXIN REMOVAL
140260.020	02	WO	CA2006/001819	11/07/2006			METHODS AND PROCESSES OF CONTROLLING FERMENTATION
140260.020	05	CA	2632457	11/07/2006			METHODS AND PROCESSES OF CONTROLLING FERMENTATION
140260.021	01	US	12/447748	12/09/2009			IMMUNOTOXIN FUSIONS COMPRISING AN ANTIBODY

PATENT

REEL: 031144 FRAME: 0375

Case Number	Sub Case	Country	Application Number	File Date	Patent Number	Issue Date	Application Title
140260.021	02	WO	CA2007/001927	10/30/2007			FRAGMENT AND A PLANT TOXIN LINKED BY PROTEASE CLEAVABLE LINKERS
140260.021	05	CA	2668017	10/30/2007			IMMUNOTOXIN FUSIONS COMPRISING AN ANTIBODY FRAGMENT AND A PLANT TOXIN LINKED BY PROTEASE CLEAVABLE LINKERS
140260.024	00	US	61/811360	04/12/2013			IMPROVED CONJUGATES
							COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA